Replies to post #488 on Merck and Co Inc (MRK)

[north40000]

"A combination with Zocor[a statin] might make sense, but Zocor has been off-patent for several years, and MRK no longer has any interest in it."

IMO, MRK might well be interested in buying Amarin, with AMRN's NCE status for Vascepa, a patent portfolio encompassing Vascepa + statins extending to 2030, analyst projections of market/revenue size, continued increase in prescriptions as well as market share[now > %50% vis a vis Lovaza or gLovaza], and PTs of $30-50 per share reflecting Vascepa market of > $10B. My own off-label scrip for FDA-approved Vascepa of 6+ years duration has resulted, in light of insurance coverage, in my total co-pay of $36/year.

Original post in this thread, all links included:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151534457

[couldbebetter]

Dew, The fact that higher blood EPA levels are associated with good
medical outcomes and low blood EPA levels are associated with more
negative outcomes, even in various types of cancer, the prospect
of a combination of Keytruda and Vascepa might be worthy of consideration.